How Growth-Hormone Peptides Actually Work: The GHRH Family, the Stack Logic, and the Honest Risks

TL;DR

• The axis is a chain - the pituitary pulses GH, the liver answers with IGF-1, and IGF-1 does much of the tissue work.
• GHRH analogues wake the pulse - sermorelin, mod GRF(1–29), CJC-1295 and tesamorelin differ mainly in how long they last.
• GHRPs turn up the volume - they hit the ghrelin receptor, raise pulse amplitude and lift the somatostatin brake; ipamorelin is the selective one.
• Only tesamorelin is FDA-approved - for HIV-associated lipodystrophy, on trials showing roughly 15–18% visceral-fat reduction over about 26 weeks.
• IGF-1 LR3 and follistatin are a different risk class - they bypass the regulated axis, and the human safety ledger for them is essentially blank.
• Active cancer is a full stop - the entire point of this axis is raising a growth signal, so physician screening comes before anything else.

Evidence-tiered; primary literature only. Educational content, not medical advice or a treatment claim. No doses, protocols, or stacks are given - those are a physician determination. Most compounds named are not approved for muscle, anti-aging, or fat-loss use; several are research chemicals with little or no human data.

---

Sermorelin, ipamorelin, hexarelin, tesamorelin, mod GRF, CJC-1295, IGF-1 LR3 - the names read like they were generated during a power outage, and the marketing treats them as interchangeable "muscle peptides." They aren't. Nearly all of them make sense the moment you understand one thing: the growth hormone → IGF-1 axis, and which knob on it each compound turns. Once you have that map, the alphabet soup sorts itself into a small number of jobs - and the genuinely risky ones become easy to spot.

This piece is the framework, not a protocol. Where it names a clinical use, that's research context; where it names a compound's status, we'll be precise, because in this category the difference between approved, off-label, and research chemical is the whole story.

The axis: a signal, a relay, and the hormone that does the work

Picture the pituitary - the small gland at the base of the brain - as a DJ. Every so often it drops a track: a pulse of growth hormone (GH). GH itself isn't mainly what builds and repairs tissue. Each pulse travels to the liver, which responds by producing IGF-1 (insulin-like growth factor 1) - and IGF-1 is the hormone that actually drives much of the muscle-building, tissue-repair, and recovery people are chasing.

Two more details matter. GH is released in pulses, mostly during deep sleep and after hard exercise - the pulsatility is part of the physiology, not an accident. And the system is governed by a brake: somatostatin, which quiets GH release. That pulsatility is also why bloodwork on this axis reports IGF-1 rather than GH itself - what an IGF-1 level means, and what it stops short of showing, is worth understanding before reading anyone's results.

With age, the DJ plays fewer, softer tracks - GH pulse amplitude and frequency decline from roughly the third decade onward, a pattern often called somatopause. Crucially, in most people the pituitary itself is still capable; it's the signalling that fades. That single fact is why an entire class of compounds exists: not to replace GH, but to coax the existing gland to play again. That distinction - supplying the finished hormone versus prompting the gland to release its own - is set out in full in recombinant GH versus secretagogues, head to head; this page stays with how the secretagogues themselves work.

Job #1: GHRH analogues - "wake the DJ" (pulsatile)

Growth-hormone-releasing hormone (GHRH) is the body's own "play a track" signal. Native human GHRH is 44 amino acids long, and its first 29 are the shortest fully active fragment - which is why so many of these compounds are built on a "1–29" backbone. They bind the GHRH receptor on the pituitary and prompt a pulse. They differ mainly in how long they last:

• Sermorelin is the original - a synthetic GRF(1–29). It has the shortest half-life of the group, because the enzyme DPP-4 clears it quickly, so it produces a brief, physiologic-looking pulse (and is often valued for sleep-quality effects). Worth knowing precisely: sermorelin was FDA-approved (as Geref, 1997) for growth-hormone-deficiency testing/treatment in children, and was discontinued in 2008 for commercial reasons, not safety. It now exists only as a compounded preparation - real molecule, but no longer an FDA-approved finished product.
• Mod GRF(1–29) - colloquially "CJC-1295 without DAC" - is the same backbone with a few amino-acid substitutions engineered to resist DPP-4, extending its window to roughly half an hour. A slightly longer sparkler.
• CJC-1295 with DAC adds a "drug affinity complex" that binds albumin in the blood, so it lingers for days (roughly a week of activity). This is a real departure from physiology: instead of discrete pulses it produces a sustained elevation - a so-called "GH bleed." Human data exist (Teichman and colleagues, J Clin Endocrinol Metab, 2006, showed prolonged GH/IGF-1 elevation), but losing pulsatility is a meaningful trade, not a free upgrade.
• Tesamorelin is the outlier and the only one with a real approval. It's the full 44-amino-acid GHRH stabilised with a fatty-acid (trans-3-hexenoic acid) modification; it clears quickly but elevates GH for close to a day. It is FDA-approved (Egrifta, 2010) - but only to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. The pivotal trials (Falutz and colleagues, New England Journal of Medicine, 2007, with later safety-extension data) showed roughly 15–18% reductions in visceral fat over about 26 weeks. That approval is specific; every muscle, anti-aging, or general fat-loss use is off-label, and tesamorelin also carries the clearest side-effect record of the group (more on that below).

Job #2: GHRPs / ghrelin-receptor agonists - "turn up the volume" (amplitude)

If GHRH analogues wake the DJ, the growth-hormone-releasing peptides (GHRPs) are the hype-man yelling "louder." They act on a different receptor (the ghrelin/GHS receptor), and they do two things: increase the amplitude of GH pulses and suppress somatostatin (lift the brake), producing a cleaner, bigger signal.

The members differ mostly in their off-target effects:

• Ipamorelin is the selective one. The foundational pharmacology (Raun and colleagues, European Journal of Endocrinology, 1998) established that it releases GH without meaningfully raising cortisol, prolactin, or ACTH - which is exactly why it became the preferred GHRP for non-disease use.
• GHRP-6 drives intense hunger (strong ghrelin-pathway activation). GHRP-2 can raise cortisol and prolactin at higher doses. Hexarelin is potent but has documented cardiovascular effects and tends to desensitise. None of these is "wrong," but the selectivity differences are real clinical distinctions, not marketing.

(For completeness: macimorelin / Macrilen is a ghrelin-receptor agonist that did reach FDA approval - as a diagnostic agent for adult GH deficiency, not a therapy.)

Why people pair them: the synergy - and why that isn't a recipe

The reason you constantly see a GHRH analogue paired with a GHRP (e.g., tesamorelin or CJC-1295 with ipamorelin) is mechanistic: one increases pulse frequency/initiation, the other increases amplitude and removes the somatostatin brake. Combined, they tend to produce more GH release than either alone - frequency × amplitude.

That the mechanisms are complementary is a reason to find the pairing interesting; it is not a validated home protocol. Combined dosing, timing, and whether any of this is appropriate for a given person are clinical decisions made against bloodwork - not something to reverse-engineer from a video. We explain the rationale; a physician prescribes.

The high-risk tier: where people actually get hurt

The compounds above mostly work with the body's own regulated, pulsatile system. The next two bypass it - which is precisely why they're higher-risk and thin on human safety data.

• IGF-1 LR3 (Long R3 IGF-1) is a synthetic, modified IGF-1 built so it barely binds the IGF-binding proteins that normally restrain it - making it far longer-acting and more potent, and letting it act directly on tissues, skipping the GH pathway entirely. It was created as a research reagent (to study IGF-1, which is otherwise short-lived and protein-bound); using it on a body is an off-script leap. The same potency that's attractive is the problem: because IGF-1 has insulin-like activity, it can drop blood sugar and worsen insulin resistance, and the chronically elevated, unregulated IGF-1 signalling raises theoretical concerns about organ/visceral growth and cancer (IGF-1 is mitogenic; elevated IGF-1 is epidemiologically linked to several cancers - Renehan and colleagues, Lancet, 2004). Human safety data for this use are essentially absent.
• Follistatin works by inhibiting myostatin, the body's natural brake on muscle growth - "cutting the brakes." In principle that produces dramatic muscle size; in practice the human evidence is scant, dosing is unreliable, results are inconsistent, and size does not reliably equal strength or function. It sits firmly in research-chemical territory.

These aren't "advanced" versions of the safer compounds. They're a different risk class, and the honest framing is that the safety ledger is mostly blank.

The honest limits (read this part twice)

• Approval status, stated accurately. Of everything here, only tesamorelin is FDA-approved - and only for HIV-associated lipodystrophy. Sermorelin's approval lapsed in 2008 and survives as a compounded product. Everything else is off-label or a research chemical. Anyone implying broader approval is misreading the label.
• Human data is a gradient, not a yes/no. GHRH analogues and ipamorelin/most GHRPs actually have meaningful human data. IGF-1 LR3 and follistatin have very little. "It's a peptide" tells you nothing about how much we actually know.
• Side effects are real, and best documented for the most-studied compound. Tesamorelin's record includes fluid retention, joint stiffness and pain, carpal-tunnel-type symptoms, and glucose intolerance / insulin resistance - the classic signature of pushing GH/IGF-1 signalling. Forcing the axis "too hard, too consistently" is exactly where those show up.
• The cancer hard stop. Because the entire point of this axis is to raise IGF-1 - a growth signal - stimulating the GH/IGF-1 pathway is contraindicated in anyone with active cancer or a strong predisposition. This isn't a hedge; it's a full stop, and it's a physician screening decision before anything else.

The bigger point

The reason the GH-axis framework is worth learning is that it turns a marketing jumble into a small set of honest questions. Are you trying to nudge a fading but intact signal (the GHRH/GHRP logic, working with pulsatility), or to override the system (the IGF-1 LR3/follistatin logic, where the data thin out and the risks climb)? Those are very different propositions with very different safety profiles, and conflating them is how people get into trouble.

And none of it is a substitute for measuring - or for the free lever most people ignore. The single largest natural GH pulse of the day is released during deep, slow-wave sleep, so protecting that sleep does more for the axis than most compounds claim to; see how peptides affect deep sleep and the GH pulse. The axis itself is read through markers like IGF-1 and fasting insulin/glucose, interpreted by a clinician who'll first rule out the reasons not to touch it. If you're exploring this seriously, that baseline - and that physician - is the actual first step, not the order page.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore sermorelin.

---

Educational content. Not medical advice and not a treatment claim. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy; sermorelin's branded approval was discontinued in 2008 and it is now compounded; CJC-1295, ipamorelin, the other GHRPs, IGF-1 LR3, and follistatin are not FDA-approved for the uses discussed and several are research-grade with minimal human data. Stimulating the GH/IGF-1 axis is contraindicated in active malignancy. Any use is investigational and physician-supervised. For Malaysia-facing care, health and treatment claims are subject to MAB requirements.

Primary references

• Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. (PMID 18057338) - and Falutz J, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311–322.
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. (PMID 9784065)
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139–157.
• Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–1353.
• Sermorelin (Geref) - FDA approval 1997; manufacturer discontinued 2008 for commercial reasons. (Regulatory status reference; no current FDA-approved finished product.)